HighTower Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-100
Closed -$328 4012
2025
Q1
$328 Sell
100
-100
-50% -$8.94K ﹤0.01% 3692
2024
Q4
$2.96K Hold
200
﹤0.01% 3660
2024
Q3
$4.42K Hold
200
﹤0.01% 3599
2024
Q2
$3.84K Hold
200
﹤0.01% 3497
2024
Q1
$4.66K Buy
+200
New +$18.6K ﹤0.01% 3445
2022
Q3
Sell
-15,000
Closed -$84K 3433
2022
Q2
$84K Buy
15,000
+14,953
+31,815% +$1.12M ﹤0.01% 2827
2022
Q1
$4K Buy
+47
New +$4.34K ﹤0.01% 3294
2021
Q3
Sell
-39,500
Closed -$97K 3458
2021
Q2
$97K Buy
+39,500
New +$5.19M ﹤0.01% 2819
2021
Q1
Sell
-50
Closed -$105K 3284
2020
Q4
$105K Sell
50
-5,950
-99% -$762K ﹤0.01% 2343
2020
Q3
$25K Buy
+6,000
New +$673K ﹤0.01% 2356
2018
Q1
Sell
-3,000
Closed -$11K 2358
2017
Q4
$11K Buy
+3,000
New +$251K ﹤0.01% 2181

Other funds holding XBI

HighTower Advisors's XBI Position: Q1 2026 in Review

HighTower Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q1 2026, buying an estimated $1.19M and bringing the position to 82,081 shares worth $10.5M. The position accounts for 0.01% of the portfolio, ranked #864.

HighTower Advisors first reported a position in XBI in Q2 2013 and has held it in 48 quarters since. The position peaked at $42M in Q2 2022. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • HighTower Advisors held 82,081 shares of State Street SPDR S&P Biotech ETF worth $10.5M as of Q1 2026.
  • HighTower Advisors bought 9,559 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.19M.
  • State Street SPDR S&P Biotech ETF made up 0.01% of HighTower Advisors's portfolio in Q1 2026, its #864 holding.
  • HighTower Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 48 quarters since.
  • HighTower Advisors's State Street SPDR S&P Biotech ETF position peaked at $42M in Q2 2022.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.